Back

Notification report


Full notification file


General information

Notification Number
B/NL/05/006

Member State to which the notification was sent
Netherlands

Date of acknowledgement from the Member State Competent Authority
24/11/2005

Title of the Project
Adjuvant IL-12 immuno-gene therapy prior to radical prostatectomy in patients with prostate cancer

Proposed period of release:
01/07/2006 to 01/07/2008

Name of the Institute(s) or Company(ies)
Erasmus MC, University Medical Center Rotterdam, ;


3. Is the same GMO release planned elsewhere in the Community?
No

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Mastadenovirus (genus), human adenovirus (species). The GMO is a replication incompetent recombinant adenovirus (human serotype 5) containing the human gene for interleukin-12 (referred to as Adv/IL-12)

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
human serotype 5 (Ad5)Mastadenovirushuman adenovirussubgroup Chuman serotype 5 (Ad5)

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known